Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Among authors: kiladjian jj. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.
Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H; PROUD-PV Study Group. Kiladjian JJ, et al. Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24. Leukemia. 2022. PMID: 35210530 Free PMC article. No abstract available.
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.
Harrison C, Yacoub A, Scott B, Mead A, Gerds AT, Kiladjian JJ, Mesa R, Egyed M, Scheid C, Gutierrez VG, O'Sullivan J, Buckley S, Kanellopoulos K, Mascarenhas J. Harrison C, et al. Among authors: kiladjian jj. Haematologica. 2023 Jul 1;108(7):1960-1964. doi: 10.3324/haematol.2022.282089. Haematologica. 2023. PMID: 36601980 Free PMC article. No abstract available.
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.
Shomali W, Colucci P, George TI, Kiladjian JJ, Langford C, Patel JL, Reiter A, Vannucchi AM, Gotlib J. Shomali W, et al. Among authors: kiladjian jj. Leukemia. 2023 May;37(5):981-987. doi: 10.1038/s41375-023-01859-3. Epub 2023 Apr 19. Leukemia. 2023. PMID: 37076693 Free PMC article. Review. No abstract available.
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.
Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, Zaiac M, Morelli M, Smyth A, Redondo S, Bigan E, Ruhl M, Meier C, Beffy M, Kiladjian JJ. Verstovsek S, et al. Among authors: kiladjian jj. Biomedicines. 2023 Jul 7;11(7):1925. doi: 10.3390/biomedicines11071925. Biomedicines. 2023. PMID: 37509564 Free PMC article.
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S. Oh ST, et al. Among authors: kiladjian jj. Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151. Blood Adv. 2023. PMID: 37552106 Free PMC article.
Incidence of blast phase in myelofibrosis according to anemia severity.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian JJ, Elli EM, Polverelli N, Gotlib J, Albano F, Silver RT, Benevolo G, Ross DM, Devos T, Borsani O, Barbui T, Porta MGD, Bertù L, Komrokji R, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: kiladjian jj. EJHaem. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601878 Free PMC article.
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: kiladjian jj. Leukemia. 2023 Oct;37(10):2129-2132. doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26. Leukemia. 2023. PMID: 37634011 Free PMC article. No abstract available.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Hudgens S, Verstovsek S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan D, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AA, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Mesa RA. Hudgens S, et al. Among authors: kiladjian jj. Value Health. 2024 May;27(5):607-613. doi: 10.1016/j.jval.2024.01.014. Epub 2024 Feb 2. Value Health. 2024. PMID: 38311180 Clinical Trial.
280 results